Literature DB >> 15671294

Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.

Leena Pitkänen1, Veli-Pekka Ranta, Hanna Moilanen, Arto Urtti.   

Abstract

PURPOSE: To determine the effects of solute molecular weight and lipophilicity on the permeability of a retinal pigment epithelium (RPE)-choroid preparation.
METHODS: Fresh RPE-choroid specimens from bovine eyes were placed in diffusion chambers for permeability experiments with carboxyfluorescein, fluorescein isothiocyanate (FITC)-labeled dextrans with molecular masses from 4 to 80 kDa, and beta-blockers exhibiting a wide range of lipophilicity (atenolol, nadolol, pindolol, timolol, metoprolol, and betaxolol). Permeability experiments were performed both in the choroid-to-retina (inward) direction and in the retina-to-choroid (outward) direction. Carboxyfluorescein and FITC-dextrans were determined by fluorometry, and beta-blockers by HPLC. The transepithelial electrical resistance and potential difference were monitored during the experiments.
RESULTS: Permeability of the fluorescent FITC-dextran probes through RPE-choroid decreased significantly with the increasing size of the probe. RPE-choroid was 35 times more permeable to carboxyfluorescein (376 Da) than to FITC-dextran 80 kDa. The permeabilities of lipophilic beta-blockers were up to 8 and 20 times higher than that of hydrophilic atenolol and carboxyfluorescein, respectively. The lag time of solute flux across the RPE-choroid increased with the molecular weight and lipophilicity. Compared with published data on isolated sclera, bovine RPE-choroid was 10 to 100 times less permeable to hydrophilic compounds and macromolecules. The permeability of lipophilic molecules in RPE-choroid was in the same range as in the sclera.
CONCLUSIONS: RPE is a major barrier and may be the rate-limiting factor in the retinal delivery of hydrophilic drugs and macromolecules through the transscleral route. For lipophilic molecules, RPE-choroid, and sclera are approximately equal barriers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671294     DOI: 10.1167/iovs.04-1051

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  63 in total

1.  In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.

Authors:  Paul Missel; James Chastain; Ashim Mitra; Uday Kompella; Viral Kansara; Sridhar Duvvuri; Aniruddha Amrite; Narayan Cheruvu
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

Review 2.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

3.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

4.  Confocal imaging to quantify passive transport across biomimetic lipid membranes.

Authors:  Su Li; Peichi Hu; Noah Malmstadt
Journal:  Anal Chem       Date:  2010-09-15       Impact factor: 6.986

5.  Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Authors:  Rajendra S Kadam; Narayan P S Cheruvu; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

6.  Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.

Authors:  Ram K Balachandran; Victor H Barocas
Journal:  Pharm Res       Date:  2008-08-05       Impact factor: 4.200

7.  Extended Pharmacokinetic Model of the Rabbit Eye for Intravitreal and Intracameral Injections of Macromolecules: Quantitative Analysis of Anterior and Posterior Elimination Pathways.

Authors:  Marko Lamminsalo; Ella Taskinen; Timo Karvinen; Astrid Subrizi; Lasse Murtomäki; Arto Urtti; Veli-Pekka Ranta
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

8.  Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model.

Authors:  Timothy W Olsen; Xiao Feng; Kathy Wabner; Karl Csaky; Stefan Pambuccian; J Douglas Cameron
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-01       Impact factor: 4.799

Review 9.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

10.  Effect of diabetes on transscleral delivery of celecoxib.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Pharm Res       Date:  2008-11-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.